Influence of baseline characteristics on subjective improvement of dry eye after intense pulsed light therapy

To identify baseline clinical signs and symptoms associated with response to intense pulsed light (IPL) combined with meibomian gland expression in dry eye disease (DED), and to develop machine learning (ML) models for individualized outcome prediction. This retrospective study analyzed 100 eyes fro...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Contact lens & anterior eye s. 102514
Hlavní autoři: Carrillo-Pulido, Miriam, Ortiz-Peregrina, Sonia, López Pérez, María Dolores, Cano-Ortiz, Antonio, González-Cruces, Timoteo
Médium: Journal Article
Jazyk:angličtina
Vydáno: England 07.10.2025
Témata:
ISSN:1367-0484, 1476-5411, 1476-5411
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract To identify baseline clinical signs and symptoms associated with response to intense pulsed light (IPL) combined with meibomian gland expression in dry eye disease (DED), and to develop machine learning (ML) models for individualized outcome prediction. This retrospective study analyzed 100 eyes from 100 DED patients (aged 58.6 ± 13.4 years) treated with IPL and meibomian gland expression. Baseline parameters assessed with the Antares system included meibomian gland loss (MGL), tear meniscus height (TMH), non-invasive tear break-up time (NIBUT), conjunctival hyperemia, and Ocular Surface Disease Index (OSDI). Patients were stratified by change in OSDI after treatment (ΔOSDI): Class 1 (no improvement), Class 2 (mild improvement), and Class 3 (clear improvement). Several ML models were trained to predict ΔOSDI from baseline parameters. IPL significantly improved both symptoms and signs. OSDI decreased from 44.65 ± 18.3 to 28.47 ± 19.3 (p < 0.001), NIBUT increased from 4.5 ± 3.2 to 7.5 ± 6.5 s (p < 0.001), and TMH and conjunctival hyperemia also improved (p < 0.001), while MGL and BCVA remained stable. Greater improvement was observed in patients with higher baseline OSDI (p = 0.001). The XGBoost algorithm achieved the highest predictive performance (AUC-ROC = 0.77), with OSDI and NIBUT as the strongest predictors based on SHAP analysis. IPL combined with meibomian gland expression improves symptoms and signs in DED, particularly in patients with more severe baseline symptoms. Baseline OSDI and NIBUT were the strongest predictors of response. ML models demonstrated moderate accuracy, supporting their potential role in personalized DED treatment strategies.
AbstractList To identify baseline clinical signs and symptoms associated with response to intense pulsed light (IPL) combined with meibomian gland expression in dry eye disease (DED), and to develop machine learning (ML) models for individualized outcome prediction.PURPOSETo identify baseline clinical signs and symptoms associated with response to intense pulsed light (IPL) combined with meibomian gland expression in dry eye disease (DED), and to develop machine learning (ML) models for individualized outcome prediction.This retrospective study analyzed 100 eyes from 100 DED patients (aged 58.6 ± 13.4 years) treated with IPL and meibomian gland expression. Baseline parameters assessed with the Antares system included meibomian gland loss (MGL), tear meniscus height (TMH), non-invasive tear break-up time (NIBUT), conjunctival hyperemia, and Ocular Surface Disease Index (OSDI). Patients were stratified by change in OSDI after treatment (ΔOSDI): Class 1 (no improvement), Class 2 (mild improvement), and Class 3 (clear improvement). Several ML models were trained to predict ΔOSDI from baseline parameters.METHODSThis retrospective study analyzed 100 eyes from 100 DED patients (aged 58.6 ± 13.4 years) treated with IPL and meibomian gland expression. Baseline parameters assessed with the Antares system included meibomian gland loss (MGL), tear meniscus height (TMH), non-invasive tear break-up time (NIBUT), conjunctival hyperemia, and Ocular Surface Disease Index (OSDI). Patients were stratified by change in OSDI after treatment (ΔOSDI): Class 1 (no improvement), Class 2 (mild improvement), and Class 3 (clear improvement). Several ML models were trained to predict ΔOSDI from baseline parameters.IPL significantly improved both symptoms and signs. OSDI decreased from 44.65 ± 18.3 to 28.47 ± 19.3 (p < 0.001), NIBUT increased from 4.5 ± 3.2 to 7.5 ± 6.5 s (p < 0.001), and TMH and conjunctival hyperemia also improved (p < 0.001), while MGL and BCVA remained stable. Greater improvement was observed in patients with higher baseline OSDI (p = 0.001). The XGBoost algorithm achieved the highest predictive performance (AUC-ROC = 0.77), with OSDI and NIBUT as the strongest predictors based on SHAP analysis.RESULTSIPL significantly improved both symptoms and signs. OSDI decreased from 44.65 ± 18.3 to 28.47 ± 19.3 (p < 0.001), NIBUT increased from 4.5 ± 3.2 to 7.5 ± 6.5 s (p < 0.001), and TMH and conjunctival hyperemia also improved (p < 0.001), while MGL and BCVA remained stable. Greater improvement was observed in patients with higher baseline OSDI (p = 0.001). The XGBoost algorithm achieved the highest predictive performance (AUC-ROC = 0.77), with OSDI and NIBUT as the strongest predictors based on SHAP analysis.IPL combined with meibomian gland expression improves symptoms and signs in DED, particularly in patients with more severe baseline symptoms. Baseline OSDI and NIBUT were the strongest predictors of response. ML models demonstrated moderate accuracy, supporting their potential role in personalized DED treatment strategies.CONCLUSIONSIPL combined with meibomian gland expression improves symptoms and signs in DED, particularly in patients with more severe baseline symptoms. Baseline OSDI and NIBUT were the strongest predictors of response. ML models demonstrated moderate accuracy, supporting their potential role in personalized DED treatment strategies.
To identify baseline clinical signs and symptoms associated with response to intense pulsed light (IPL) combined with meibomian gland expression in dry eye disease (DED), and to develop machine learning (ML) models for individualized outcome prediction. This retrospective study analyzed 100 eyes from 100 DED patients (aged 58.6 ± 13.4 years) treated with IPL and meibomian gland expression. Baseline parameters assessed with the Antares system included meibomian gland loss (MGL), tear meniscus height (TMH), non-invasive tear break-up time (NIBUT), conjunctival hyperemia, and Ocular Surface Disease Index (OSDI). Patients were stratified by change in OSDI after treatment (ΔOSDI): Class 1 (no improvement), Class 2 (mild improvement), and Class 3 (clear improvement). Several ML models were trained to predict ΔOSDI from baseline parameters. IPL significantly improved both symptoms and signs. OSDI decreased from 44.65 ± 18.3 to 28.47 ± 19.3 (p < 0.001), NIBUT increased from 4.5 ± 3.2 to 7.5 ± 6.5 s (p < 0.001), and TMH and conjunctival hyperemia also improved (p < 0.001), while MGL and BCVA remained stable. Greater improvement was observed in patients with higher baseline OSDI (p = 0.001). The XGBoost algorithm achieved the highest predictive performance (AUC-ROC = 0.77), with OSDI and NIBUT as the strongest predictors based on SHAP analysis. IPL combined with meibomian gland expression improves symptoms and signs in DED, particularly in patients with more severe baseline symptoms. Baseline OSDI and NIBUT were the strongest predictors of response. ML models demonstrated moderate accuracy, supporting their potential role in personalized DED treatment strategies.
ArticleNumber 102514
Author Cano-Ortiz, Antonio
López Pérez, María Dolores
Ortiz-Peregrina, Sonia
González-Cruces, Timoteo
Carrillo-Pulido, Miriam
Author_xml – sequence: 1
  givenname: Miriam
  orcidid: 0009-0004-8439-2749
  surname: Carrillo-Pulido
  fullname: Carrillo-Pulido, Miriam
– sequence: 2
  givenname: Sonia
  surname: Ortiz-Peregrina
  fullname: Ortiz-Peregrina, Sonia
– sequence: 3
  givenname: María Dolores
  surname: López Pérez
  fullname: López Pérez, María Dolores
– sequence: 4
  givenname: Antonio
  surname: Cano-Ortiz
  fullname: Cano-Ortiz, Antonio
– sequence: 5
  givenname: Timoteo
  surname: González-Cruces
  fullname: González-Cruces, Timoteo
BackLink https://www.ncbi.nlm.nih.gov/pubmed/41062344$$D View this record in MEDLINE/PubMed
BookMark eNo9kctuwyAQRVGVqnm0P9BFxbIbp4CxiZdV1EekSN20a0RgaLBsnIIdKX9frKRdMbo6d4TmzNHEdx4QuqdkSQktn-qlbhQsGWFFClhB-RWaUS7KrOCUTtKclyIjfMWnaB5jTVKpqsgNmnJKSpZzPkPtxttmAK8BdxbvVITGecB6r4LSPQQXe6cj7jyOw64G3bsjYNceQneEFnw_tkw4YTgBVjYVsPM9-Aj4MDQRDG7c977H_R6COpxu0bVVKb67vAv09fryuX7Pth9vm_XzNtOMFjwriTY6Z1xwqIhlprCMG0JKwQ0rbVVpI7gAanbEaqGNXaVQkKKiQGnOlMkX6PG8N_3zZ4DYy9ZFDU2jPHRDlDkrKiIEqYqEPlzQYdeCkYfgWhVO8u9ECWBnQIcuxgD2H6FEjh5kLUcPcvQgzx7yXzjPfSQ
Cites_doi 10.1167/iovs.14-15764
10.1016/j.jtos.2017.05.001
10.1016/j.jtos.2017.05.008
10.1167/iovs.10-6997b
10.2147/OPTH.S318885
10.25289/ML.2019.8.2.50
10.3390/jcm10163573
10.1177/11206721231199121
10.1097/ICL.0000000000000307
10.2147/OPTH.S321764
10.1097/ICL.0000000000000711
10.1111/opo.13302
10.1016/j.jcjo.2016.01.005
10.1016/j.jtos.2025.02.008
10.1007/s10792-020-01292-w
10.1016/j.jtos.2025.02.005
10.1016/j.ajo.2025.05.033
10.1080/08820538.2020.1755321
10.1016/j.jtos.2017.05.011
10.1080/08820538.2018.1551496
10.21037/apm-21-1303
10.1097/ICL.0000000000000958
10.1016/j.jtos.2023.01.005
10.1016/j.jtos.2017.05.003
10.3390/medicina57060619
10.1016/j.heliyon.2024.e36021
10.1111/opo.13373
10.1016/j.jtos.2017.05.006
10.3390/diagnostics12123167
10.1167/iovs.10-6997e
ContentType Journal Article
Copyright Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Copyright_xml – notice: Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.
DBID AAYXX
CITATION
NPM
7X8
DOI 10.1016/j.clae.2025.102514
DatabaseName CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1476-5411
ExternalDocumentID 41062344
10_1016_j_clae_2025_102514
Genre Journal Article
GroupedDBID ---
--K
--M
.1-
.FO
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29F
4.4
457
4G.
53G
5GY
5VS
6PF
7-5
71M
8P~
9DU
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAWTL
AAXKI
AAXUO
AAYWO
AAYXX
ABBQC
ABJNI
ABMAC
ABMZM
ABWVN
ABXDB
ACDAQ
ACGFS
ACIEU
ACIUM
ACJTP
ACLOT
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXBA
AFXIZ
AGHFR
AGQPQ
AGUBO
AGYEJ
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
CITATION
COF
CS3
EBS
EFJIC
EFKBS
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HVGLF
HZ~
IHE
J1W
KOM
M41
MO0
N9A
O-L
O9-
OAUVE
OF-
OPF
OQ~
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SDF
SDG
SEL
SES
SEW
SNG
SPCBC
SSH
SSZ
T5K
Z5R
~G-
~HD
NPM
7X8
ID FETCH-LOGICAL-c2154-60cdc32474e90f2d5f24d00674d26f99cd747e1db0fc7cdf86f970591e1132ad3
ISSN 1367-0484
1476-5411
IngestDate Thu Oct 09 19:01:06 EDT 2025
Fri Oct 10 01:50:40 EDT 2025
Sat Nov 29 06:49:50 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Intense pulsed light therapy
Dry eye disease
Meibomian gland dysfunction
Predictive algorithms
Machine learning
Language English
License Copyright © 2025 The Author(s). Published by Elsevier Ltd.. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c2154-60cdc32474e90f2d5f24d00674d26f99cd747e1db0fc7cdf86f970591e1132ad3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0009-0004-8439-2749
OpenAccessLink https://www.contactlensjournal.com/article/S1367-0484(25)00148-1/pdf
PMID 41062344
PQID 3259077095
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3259077095
pubmed_primary_41062344
crossref_primary_10_1016_j_clae_2025_102514
PublicationCentury 2000
PublicationDate 2025-Oct-07
PublicationDateYYYYMMDD 2025-10-07
PublicationDate_xml – month: 10
  year: 2025
  text: 2025-Oct-07
  day: 07
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Contact lens & anterior eye
PublicationTitleAlternate Cont Lens Anterior Eye
PublicationYear 2025
References Garaszczuk (10.1016/j.clae.2025.102514_b0120) 2024; 44
Jones (10.1016/j.clae.2025.102514_b0035) 2017; 15
Bron (10.1016/j.clae.2025.102514_b0025) 2017; 15
Gupta (10.1016/j.clae.2025.102514_b0080) 2016; 51
Garza-Leon (10.1016/j.clae.2025.102514_b0100) 2020; 40
Stapleton (10.1016/j.clae.2025.102514_b0005) 2017; 15
Wolffsohn (10.1016/j.clae.2025.102514_b0010) 2025
Goo (10.1016/j.clae.2025.102514_b0130) 2019; 8
Gala-Núñez (10.1016/j.clae.2025.102514_b0075) 2024; 44
Ballesteros-Sánchez (10.1016/j.clae.2025.102514_b0085) 2023; 49
Schaumberg (10.1016/j.clae.2025.102514_b0140) 2011; 52
Yan (10.1016/j.clae.2025.102514_b0065) 2021; 10
Abdelmotaal (10.1016/j.clae.2025.102514_b0175) 2023; 28
Garza-Leon (10.1016/j.clae.2025.102514_b0105) 2017; 91
Sanal Dogan (10.1016/j.clae.2025.102514_b0110) 2018; 44
Craig (10.1016/j.clae.2025.102514_b0125) 2015; 56
Solomos (10.1016/j.clae.2025.102514_b0145) 2021; 57
Craig (10.1016/j.clae.2025.102514_b0015) 2017; 15
Nair (10.1016/j.clae.2025.102514_b0165) 2024; 16
Iradier (10.1016/j.clae.2025.102514_b0060) 2021; 10
Yan (10.1016/j.clae.2025.102514_b0070) 2021; 47
Consejo (10.1016/j.clae.2025.102514_b0115) 2019; 34
Lee (10.1016/j.clae.2025.102514_b0170) 2020; 35
Nelson (10.1016/j.clae.2025.102514_b0040) 2011; 52
Sánchez-González (10.1016/j.clae.2025.102514_b0090) 2022; 10
Riley (10.1016/j.clae.2025.102514_b0095) 2020; 18
Ballesteros-Sánchez (10.1016/j.clae.2025.102514_b0055) 2025; 37
Chase (10.1016/j.clae.2025.102514_b0155) 2021; 15
Park (10.1016/j.clae.2025.102514_b0135) 2022; 12
Marta (10.1016/j.clae.2025.102514_b0050) 2021; 15
Kandel (10.1016/j.clae.2025.102514_b0030) 2025; 37
Benitez-Del-Castillo (10.1016/j.clae.2025.102514_b0045) 2024; 34
Graham (10.1016/j.clae.2025.102514_b0150) 2024; 10
Wolffsohn (10.1016/j.clae.2025.102514_b0020) 2017; 15
Yang (10.1016/j.clae.2025.102514_b0160) 2022; 12
References_xml – volume: 56
  start-page: 1965
  issue: 3
  year: 2015
  ident: 10.1016/j.clae.2025.102514_b0125
  article-title: Prospective trial of intense pulsed light for the treatment of Meibomian gland dysfunction
  publication-title: Invest Ophthalmol Vis Sci
  doi: 10.1167/iovs.14-15764
– volume: 15
  start-page: 539
  year: 2017
  ident: 10.1016/j.clae.2025.102514_b0020
  article-title: TFOS DEWS II diagnostic methodology report
  publication-title: Ocul Surf
  doi: 10.1016/j.jtos.2017.05.001
– volume: 15
  start-page: 276
  year: 2017
  ident: 10.1016/j.clae.2025.102514_b0015
  article-title: TFOS DEWS II definition and classification report
  publication-title: Ocul Surf
  doi: 10.1016/j.jtos.2017.05.008
– volume: 52
  start-page: 1930
  year: 2011
  ident: 10.1016/j.clae.2025.102514_b0040
  article-title: The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee
  publication-title: Invest Ophthalmol Vis Sci
  doi: 10.1167/iovs.10-6997b
– volume: 15
  start-page: 2803
  year: 2021
  ident: 10.1016/j.clae.2025.102514_b0050
  article-title: Intense pulsed plus low-level light therapy in meibomian gland dysfunction
  publication-title: Clin Ophthalmol
  doi: 10.2147/OPTH.S318885
– volume: 10
  issue: 9
  year: 2022
  ident: 10.1016/j.clae.2025.102514_b0090
  article-title: Dry eye disease and tear film assessment through a novel non-invasive ocular surface analyzer: the OSA protocol
  publication-title: Front Med (Lausanne)
– volume: 8
  start-page: 50
  issue: 2
  year: 2019
  ident: 10.1016/j.clae.2025.102514_b0130
  article-title: Effects of low-level light therapy at 740 nm on dry eye disease in vivo
  publication-title: Med Lasers
  doi: 10.25289/ML.2019.8.2.50
– volume: 10
  start-page: 3573
  year: 2021
  ident: 10.1016/j.clae.2025.102514_b0060
  article-title: Characterization and prediction of the clinical outcome of intense pulsed light-based treatment in dry eye associated to Meibomian gland dysfunction
  publication-title: J Clin Med
  doi: 10.3390/jcm10163573
– volume: 34
  start-page: 700
  year: 2024
  ident: 10.1016/j.clae.2025.102514_b0045
  article-title: Efficacy and safety of intense pulsed light of upper and lower eyelids in Meibomian gland dysfunction: a prospective multicentric study
  publication-title: Eur J Ophthalmol
  doi: 10.1177/11206721231199121
– volume: 44
  start-page: 113
  issue: 2
  year: 2018
  ident: 10.1016/j.clae.2025.102514_b0110
  article-title: Interexaminer reliability of meibography: upper or lower eyelid?
  publication-title: Eye Contact Lens
  doi: 10.1097/ICL.0000000000000307
– volume: 15
  start-page: 4281
  year: 2021
  ident: 10.1016/j.clae.2025.102514_b0155
  article-title: Comparison of autonomous AS-OCT deep learning algorithm and clinical dry eye tests in diagnosis of dry eye disease
  publication-title: Clin Ophthalmol
  doi: 10.2147/OPTH.S321764
– volume: 47
  start-page: 45
  issue: 1
  year: 2021
  ident: 10.1016/j.clae.2025.102514_b0070
  article-title: The efficacy of intense pulsed light combined with Meibomian gland expression for the treatment of dry eye disease due to Meibomian gland dysfunction: a multicenter, randomized controlled trial
  publication-title: Eye Contact Lens
  doi: 10.1097/ICL.0000000000000711
– volume: 44
  start-page: 727
  issue: 4
  year: 2024
  ident: 10.1016/j.clae.2025.102514_b0120
  article-title: Machine learning-based prediction of tear osmolarity for contact lens practice
  publication-title: Ophthalmic Physiol Opt
  doi: 10.1111/opo.13302
– volume: 18
  issue: 368
  year: 2020
  ident: 10.1016/j.clae.2025.102514_b0095
  article-title: Calculating the sample size required for developing a clinical prediction model
  publication-title: BMJ
– volume: 51
  start-page: 249
  issue: 4
  year: 2016
  ident: 10.1016/j.clae.2025.102514_b0080
  article-title: Outcomes of intense pulsed light therapy for treatment of evaporative dry eye disease
  publication-title: Can J Ophthalmol
  doi: 10.1016/j.jcjo.2016.01.005
– volume: 37
  start-page: 33
  year: 2025
  ident: 10.1016/j.clae.2025.102514_b0055
  article-title: Efficacy of eyelid warming devices as first-step treatment in Meibomian gland dysfunction: a systematic review with meta-analysis
  publication-title: Ocul Surf
  doi: 10.1016/j.jtos.2025.02.008
– volume: 40
  start-page: 1261
  issue: 5
  year: 2020
  ident: 10.1016/j.clae.2025.102514_b0100
  article-title: Comparison of Meibomian gland loss area measurements between two computer programs and intra-inter-observer agreement
  publication-title: Int Ophthalmol
  doi: 10.1007/s10792-020-01292-w
– volume: 37
  start-page: 11
  year: 2025
  ident: 10.1016/j.clae.2025.102514_b0030
  article-title: The impact of dry eye disease on patient-reported quality of life: a save sight dry eye registry study
  publication-title: Ocul Surf
  doi: 10.1016/j.jtos.2025.02.005
– year: 2025
  ident: 10.1016/j.clae.2025.102514_b0010
  article-title: TFOS DEWS III diagnostic methodology
  publication-title: Am J Ophthalmol
  doi: 10.1016/j.ajo.2025.05.033
– volume: 12
  issue: 1
  year: 2022
  ident: 10.1016/j.clae.2025.102514_b0135
  article-title: Effect of low-level light therapy in patients with dry eye: a prospective, randomized, observer-masked trial
  publication-title: Sci Rep
– volume: 35
  start-page: 134
  issue: 2
  year: 2020
  ident: 10.1016/j.clae.2025.102514_b0170
  article-title: Clinical accuracy of an advanced corneal topographer with tear-film analysis in functional and structural evaluation of dry eye disease
  publication-title: Semin Ophthalmol
  doi: 10.1080/08820538.2020.1755321
– volume: 15
  start-page: 438
  year: 2017
  ident: 10.1016/j.clae.2025.102514_b0025
  article-title: TFOS DEWS II pathophysiology report
  publication-title: Ocul Surf
  doi: 10.1016/j.jtos.2017.05.011
– volume: 34
  start-page: 19
  issue: 1
  year: 2019
  ident: 10.1016/j.clae.2025.102514_b0115
  article-title: Introduction to machine learning for ophthalmologists
  publication-title: Semin Ophthalmol
  doi: 10.1080/08820538.2018.1551496
– volume: 10
  issue: 7
  year: 2021
  ident: 10.1016/j.clae.2025.102514_b0065
  article-title: Efficacy and safety of intense pulsed light therapy for dry eye caused by Meibomian gland dysfunction: a randomised trial
  publication-title: Ann Palliat Med
  doi: 10.21037/apm-21-1303
– volume: 49
  start-page: 8
  issue: 1
  year: 2023
  ident: 10.1016/j.clae.2025.102514_b0085
  article-title: Intense pulse light combined with low-level light therapy in dry eye disease: a systematic review
  publication-title: Eye Contact Lens
  doi: 10.1097/ICL.0000000000000958
– volume: 28
  start-page: 90
  year: 2023
  ident: 10.1016/j.clae.2025.102514_b0175
  article-title: Detecting dry eye from ocular surface videos based on deep learning
  publication-title: Ocul Surf
  doi: 10.1016/j.jtos.2023.01.005
– volume: 16
  issue: 9
  year: 2024
  ident: 10.1016/j.clae.2025.102514_b0165
  article-title: Artificial intelligence in dry eye disease: a narrative review
  publication-title: Cureus
– volume: 15
  start-page: 334
  year: 2017
  ident: 10.1016/j.clae.2025.102514_b0005
  article-title: TFOS DEWS II epidemiology report
  publication-title: Ocul Surf
  doi: 10.1016/j.jtos.2017.05.003
– volume: 57
  start-page: 619
  issue: 6
  year: 2021
  ident: 10.1016/j.clae.2025.102514_b0145
  article-title: Meibomian gland dysfunction: intense pulsed light therapy in combination with low-level light therapy as rescue treatment
  publication-title: Medicina (Kaunas)
  doi: 10.3390/medicina57060619
– volume: 10
  issue: 17
  year: 2024
  ident: 10.1016/j.clae.2025.102514_b0150
  article-title: A machine learning approach to predicting dry eye-related signs, symptoms and diagnoses from meibography images
  publication-title: Heliyon
  doi: 10.1016/j.heliyon.2024.e36021
– volume: 44
  start-page: 1472
  issue: 7
  year: 2024
  ident: 10.1016/j.clae.2025.102514_b0075
  article-title: Development of a dry eye index as a new biomarker of dry eye disease
  publication-title: Ophthalmic Physiol Opt
  doi: 10.1111/opo.13373
– volume: 15
  start-page: 575
  year: 2017
  ident: 10.1016/j.clae.2025.102514_b0035
  article-title: TFOS DEWS II management and therapy report
  publication-title: Ocul Surf
  doi: 10.1016/j.jtos.2017.05.006
– volume: 91
  start-page: 165
  issue: 4
  year: 2017
  ident: 10.1016/j.clae.2025.102514_b0105
  article-title: A new technology for the evaluation of Meibomian glands
  publication-title: Rev Mex Oftalmol
– volume: 12
  start-page: 3167
  issue: 12
  year: 2022
  ident: 10.1016/j.clae.2025.102514_b0160
  article-title: Integration of artificial intelligence into the approach for diagnosis and monitoring of dry eye disease
  publication-title: Diagnostics
  doi: 10.3390/diagnostics12123167
– volume: 52
  start-page: 1994
  issue: 4
  year: 2011
  ident: 10.1016/j.clae.2025.102514_b0140
  article-title: The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for
  publication-title: MGD Invest Ophthalmol Vis Sci
  doi: 10.1167/iovs.10-6997e
SSID ssj0016990
Score 2.3844006
SecondaryResourceType online_first
Snippet To identify baseline clinical signs and symptoms associated with response to intense pulsed light (IPL) combined with meibomian gland expression in dry eye...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
StartPage 102514
Title Influence of baseline characteristics on subjective improvement of dry eye after intense pulsed light therapy
URI https://www.ncbi.nlm.nih.gov/pubmed/41062344
https://www.proquest.com/docview/3259077095
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals 2021
  customDbUrl:
  eissn: 1476-5411
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0016990
  issn: 1367-0484
  databaseCode: AIEXJ
  dateStart: 20210601
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1La9tAEF4cp4RcSt91H2ELvQkZ67nSMXVTmpIEQ9Pim5D2EWRkrZCtkOQn9Vd2dleSXbeB9tCLMJK9wjMfM9_sPBah9xOHx9xnru0xoG_gIVI7zkJmq55KGlMRcH1-yvczcnERzefxbDD40fXCXBekLKObm7j6r6qGe6Bs1Tr7D-ruF4Ub8BmUDldQO1z_SvGn3bEjigcqJ6WJJN0ZzAxKXzXZwpg71StZSz05XBcGMNWhe8vbA8RzXeXOraoBN8qsQoXz1nprGkE36ECWa9VxCX5spRGllZarkeK3PXymaV3nRSHtWVPkTJrKfZDKst_thX90Z894za_q3DSsfQW703uPM5Xa_-BV_M6amSx_bTbBz1OT9f-YQlRQyHpTHDlNS2nrddtxCbCe3N7ucPWYVHMu7pgbE-2T0A781kQbs-uoSMn_o0cwmxOLMS1SNRXVDca_fxkUWC01HHyIkF3PTKTcmcPdPdpD-y4J4miI9o9PT-Zf-pxVCI69bcsyFYS7rzxEB90iv7Kge0IbTXEuH6GHbWyCjw2mHqMBL5-gg_O2-uIpWvbQwlLgDlp4B1pYlngDLbwFLfUrgBYGOGANLdxCCxtoYQ0t3ELrGfr26eRy-tluj-uwKfBG3w4nlFHg58Tn8US4LBCuzxQbAlMQijimDEJX7rBsIiihTERwkwC7d7jjeG7KvOdoWMqSv0RYBDRlwJyjLFWJ-xhoahSCuckcAQ5JeCNkdeJLKjOVJenKFReJknui5J4YuY_Qu07CCRhPlRFLSy6bVeJB8D8hBMKMEXphRN-v16nq1b1PXqPDDULfoOG6bvhb9IBer_NVfYT2yDw6akHyEw8_lvo
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Influence+of+baseline+characteristics+on+subjective+improvement+of+dry+eye+after+intense+pulsed+light+therapy&rft.jtitle=Contact+lens+%26+anterior+eye&rft.au=Carrillo-Pulido%2C+Miriam&rft.au=Ortiz-Peregrina%2C+Sonia&rft.au=L%C3%B3pez+P%C3%A9rez%2C+Mar%C3%ADa+Dolores&rft.au=Cano-Ortiz%2C+Antonio&rft.date=2025-10-07&rft.eissn=1476-5411&rft.spage=102514&rft_id=info:doi/10.1016%2Fj.clae.2025.102514&rft_id=info%3Apmid%2F41062344&rft.externalDocID=41062344
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1367-0484&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1367-0484&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1367-0484&client=summon